⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213303 | 1.00 | — | — | |
| SCHEMBL2844999 | 0.90 | SPHK1 (0.31) | — | |
| SCHEMBL2316548 | 0.90 | SPHK1 (0.31) | — | |
| SCHEMBL3207970 | 0.90 | SPHK1 (0.31) | — | |
| SCHEMBL27847189 | 0.89 | SPHK1 (0.30) | — | |
| SCHEMBL27847187 | 0.89 | SPHK1 (0.30) | — | |
| SCHEMBL16053531 | 0.87 | SPHK1 (0.32) | — | |
| SCHEMBL1067660 | 0.86 | SPHK1 (0.31) | — | |
| SCHEMBL1067656 | 0.86 | SPHK1 (0.31) | — | |
| SCHEMBL3614629 | 0.86 | SPHK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8729113-B2 | 4,5-dihydro-oxazol-2yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8357712-B2 | — | — | 2013-01-22 | — | — | US | disclosed |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010010014-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1467732-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6759426-B2 | RESPIRATORY SYSTREM DISORDERS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISORDERS | PFIZER INC | 2004-07-06 | — | — | US | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |